Larimar Therapeutics Inc - LRMR Enterprise Value-to-Sales Ratio

Public company logo of Larimar Therapeutics, Inc. (LRMR)

Strong confidence from patient communities and investors bolsters the market position of Larimar Therapeutics (LRMR). This enterprise value-to-revenue chart illustrates the asset's dynamics, where the value 0.00 describes the current level. Larimar Therapeutics (LRMR) aims for a monopoly in Friedreich's ataxia therapy via the nomlabofusp protein while scaling its pipeline. Future revenues are based on the commercialization of innovative treatments for rare genetic pathologies.

Larimar Corp (LRMR): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

LRMR (Larimar Pharma): analytical breakdowns and indicator data

Fundamental company valuation:LRMR (larimartx.com)
Mass-produced product of Larimar Therapeutics Inc

Larimar Therapeutics (LRMR) delegates production and testing to external contractors, making its cost structure dependent on vendors. The EV/Sales metric assesses the total business value, net of debt, per unit of revenue. Investors utilize this ratio to determine if an asset is overvalued relative to its operating income. Low values often signal that the issuer is undervalued. By analyzing the historical EV/Sales trend, one can identify abnormal valuation deviations.